Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SONUS ECHOGEN ULTRASOUND CONTRAST AGENT NDA FILING IN EARLY 1996

This article was originally published in The Gray Sheet

Executive Summary

SONUS ECHOGEN ULTRASOUND CONTRAST AGENT NDA FILING IN EARLY 1996 is planned by the Bothell, Washington-based company, CEO Steven Quay, MD/PhD, told a Medical Investments Northwest conference in Seattle Sept. 12. A total of 45 patients of a planned 120 have completed Phase II trials, which began July 10. Initial indications will be diagnosis of cardiovascular disease, renal vascular disease/hypertension, and cancer, Quay said.

You may also be interested in...



Australia Relaxes Competition Rules To Facilitate Coronavirus Response

Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.

Interview: Izana Tests GM-CSF Drug For Coronavirus

The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.

Building A Top-10 Global OTC Player – Q&A With HRA Pharma CEO David Wright

Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months. 

UsernamePublicRestriction

Register

MT002828

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel